Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.27 -5.1%	$3.89	$1.89 ▼ $5.82	$1.34B	0.65	6.94 million shs	5.03 million shs
ADMA ADMA Biologics	$16.76 +2.3%	$18.48	$13.50 ▼ $25.67	$3.91B	0.38	3.42 million shs	4.27 million shs
CRSP CRISPR Therapeutics	$56.60 +2.1%	$52.34	$30.04 ▼ $71.13	$5.04B	1.8	3.56 million shs	2.18 million shs
LNTH Lantheus	$53.90 -3.9%	$75.41	$47.25 ▼ $118.21	$3.81B	0.14	2.05 million shs	2.95 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+5.88%	+3.69%	+12.22%	+114.29%	+67.91%
ADMA ADMA Biologics	-0.74%	-17.64%	-11.41%	-17.52%	+2.74%
CRSP CRISPR Therapeutics	+0.75%	-7.01%	-2.45%	+48.87%	+17.87%
LNTH Lantheus	-1.98%	-21.54%	-31.04%	-28.98%	-42.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	3.2311 of 5 stars	4.5	1.0	0.0	2.9	3.3	0.0
ADMA ADMA Biologics	4.2379 of 5 stars	3.7	3.0	0.0	3.1	2.5	3.1
CRSP CRISPR Therapeutics	3.5943 of 5 stars	4.3	2.0	0.0	3.1	3.3	0.6
LNTH Lantheus	4.8491 of 5 stars	4.4	3.0	4.2	3.0	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.00	87.35% Upside
ADMA ADMA Biologics	3.33	Buy	$27.67	65.08% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	26.50% Upside
LNTH Lantheus	2.71	Moderate Buy	$105.50	95.73% Upside

Current Analyst Ratings Breakdown

Latest ABCL, CRSP, LNTH, and ADMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Hold	$111.00 ➝ $63.00
8/8/2025	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/7/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$112.00 ➝ $73.00
8/7/2025	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$120.00 ➝ $70.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/14/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	44.26	N/A	N/A	$3.37 per share	1.27
ADMA ADMA Biologics	$426.45M	9.38	$0.55 per share	30.26	$1.67 per share	10.04
CRSP CRISPR Therapeutics	$37.31M	137.97	N/A	N/A	$18.81 per share	3.01
LNTH Lantheus	$1.53B	2.39	$6.82 per share	7.90	$17.16 per share	3.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.55	N/A	N/A	N/A	-511.88%	-16.17%	-12.24%	N/A
ADMA ADMA Biologics	$197.67M	$0.86	19.49	24.29	N/A	44.06%	41.01%	28.47%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	N/A
LNTH Lantheus	$312.44M	$3.76	14.34	8.54	N/A	17.82%	34.06%	19.10%	N/A

Latest ABCL, CRSP, LNTH, and ADMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	-$0.12	+$0.05	-$0.12	$7.55 million	$17.08 million
8/6/2025	Q2 2025	ADMA ADMA Biologics	$0.14	$0.15	+$0.01	$0.14	$121.77 million	$121.98 million
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	$1.57	-$0.08	$1.12	$389.69 million	$378.05 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	11.07	11.07
ADMA ADMA Biologics	0.21	5.33	2.78
CRSP CRISPR Therapeutics	N/A	16.61	16.61
LNTH Lantheus	0.49	4.29	4.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ADMA ADMA Biologics	75.68%
CRSP CRISPR Therapeutics	69.20%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
ADMA ADMA Biologics	3.70%
CRSP CRISPR Therapeutics	4.10%
LNTH Lantheus	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.83 million	212.47 million	Optionable
ADMA ADMA Biologics	530	238.73 million	229.90 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.22 million	Optionable
LNTH Lantheus	700	67.99 million	66.63 million	Optionable

ABCL, CRSP, LNTH, and ADMA Headlines

Recent News About These Companies

Goldman Sachs Sticks to Their Buy Rating for Lantheus (LNTH)

5 hours ago | theglobeandmail.com

Lantheus drops as Truist downgrades after Q2 miss

5 hours ago | msn.com

LNTH Q2 Deep Dive: Competitive Pressures and Guidance Cut Reshape Lantheus Outlook

5 hours ago | msn.com

95,180 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by Eagle Global Advisors LLC

August 12 at 7:55 AM | marketbeat.com

Lantheus downgraded to Hold from Buy at Truist

August 11 at 12:36 AM | msn.com

Lantheus downgraded to Hold at Truist on Pylarify uncertainty

August 11 at 12:36 AM | msn.com

Lantheus (NASDAQ:LNTH) Posts Earnings Results

August 10 at 7:35 PM | marketbeat.com

Mizuho Cuts Lantheus (NASDAQ:LNTH) Price Target to $70.00

August 10 at 3:25 AM | americanbankingnews.com

Ontario Teachers Pension Plan Board Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

August 9 at 5:38 AM | marketbeat.com

XTX Topco Ltd Acquires New Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH)

August 9 at 3:36 AM | marketbeat.com

William Blair Reaffirms Their Hold Rating on Lantheus (LNTH)

August 8, 2025 | theglobeandmail.com

Lantheus Holdings, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

August 8, 2025 | uk.finance.yahoo.com

Lantheus (LNTH) Q2 Revenue Falls 4%

August 8, 2025 | theglobeandmail.com

Lantheus Holdings (LNTH) Dives 28.6% on Tempered Growth Outlook

August 8, 2025 | msn.com

Lantheus (NASDAQ:LNTH) Issues FY 2025 Earnings Guidance

August 8, 2025 | marketbeat.com

JMP Securities Issues Pessimistic Forecast for Lantheus (NASDAQ:LNTH) Stock Price

August 8, 2025 | marketbeat.com

Mizuho Has Lowered Expectations for Lantheus (NASDAQ:LNTH) Stock Price

August 8, 2025 | marketbeat.com

Lantheus (NASDAQ:LNTH) Hits New 1-Year Low - Should You Sell?

August 7, 2025 | marketbeat.com

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | taiwannews.com.twT

Lantheus announces FDA review for new radioactive imaging agent

August 7, 2025 | msn.com

Why Lantheus (LNTH) Stock Is Falling Today

August 7, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL, CRSP, LNTH, and ADMA Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.27 -0.23 (-5.11%)

Closing price 04:00 PM Eastern

Extended Trading

$4.31 +0.04 (+0.96%)

As of 07:58 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ADMA Biologics NASDAQ:ADMA

$16.76 +0.38 (+2.32%)

Closing price 04:00 PM Eastern

Extended Trading

$16.70 -0.06 (-0.33%)

As of 07:59 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CRISPR Therapeutics NASDAQ:CRSP

$56.60 +1.19 (+2.15%)

Closing price 04:00 PM Eastern

Extended Trading

$56.75 +0.15 (+0.26%)

As of 07:57 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Lantheus NASDAQ:LNTH

$53.90 -2.17 (-3.87%)

Closing price 04:00 PM Eastern

Extended Trading

$54.04 +0.14 (+0.26%)

As of 07:59 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time